Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lincoff, A. M.
  • Tardif, J. C.
  • Schwartz, G. G.
  • Nicholls, S. J.
  • Ryden, L.
  • Neal, B.
  • Malmberg, K.
  • Wedel, H.
  • Buse, J. B.
  • Henry, R. R.
  • Weichert, A.
  • Cannata, R.
  • Svensson, A.
  • Volz, D.
  • Grobbee, D. E.
  • AleCardio, Investigators
  • Steinhubl, Steven

publication date

  • 2014

journal

  • JAMA-Journal of the American Medical Association  Journal

subject areas

  • Acute Coronary Syndrome
  • Aged
  • Diabetes Mellitus, Type 2
  • Double-Blind Method
  • Female
  • Humans
  • Hypoglycemic Agents
  • Kidney
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Oxazoles
  • Peroxisome Proliferator-Activated Receptors
  • Risk
  • Stroke
  • Survival Analysis
  • Thiophenes
  • Treatment Outcome
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0098-7484

Digital Object Identifier (DOI)

  • 10.1001/jama.2014.3321

PubMed ID

  • 24682069
scroll to property group menus

Additional Document Info

start page

  • 1515

end page

  • 1525

volume

  • 311

issue

  • 15

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support